Health economic issues in rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 35, Issue 6, 2006, Pages 415-425

  Kobelt, G ^a,b,c  

^a LUND UNIVERSITY   (Sweden)

^b European Health Economics SAS   (France)

^c NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; ANTIRHEUMATIC AGENT;

CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MORTALITY; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SIMULATION; STOCHASTIC MODEL; COST; ECONOMICS; OUTCOME ASSESSMENT; STATISTICAL MODEL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COSTS AND COST ANALYSIS; DISEASE PROGRESSION; HUMANS; MODELS, ECONOMIC; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 33947610184     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740601061126     Document Type: Review

References (55)

1. Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis. A systematic literature review. Pharmacoeconomics 2005;23:243-57.
2. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83.
3. Kobelt G, Lindgren P, Lindroth Y, Jacobsson L, Eberhardt K. Modeling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology 2005;44:1169-75.
4. Kobelt G, Eberhardt K, Geborek P. TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.
5. Thompson M, Leighton-Read J, Hutchings C, Paterson M Jr, Harris EH. The cost effectiveness of auranofin. Results of a randomized clinical trial. J Rheumatol 1988;15:35-42.
6. Kobelt G, Lindgren P, Young A, Eberhardt K. Cost and effects of leflunomide in the UK. Eur J Health Econ 2002;3:173-9.
7. Wong J, Singh G, Kavanough A. Estimating the cost-effectiveness of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
8. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002;29:1156-65.
9. Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
10. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with chronic conditions: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8:1-91.
11. Brennan A, Bansback N, Reynolds P, Conway P. Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62-72.
12. Barbieri M, Wong JB, Drummond M. The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics 2005;23:607-18.
13. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64:1174-9.
14. National Institute for Clinical Excellence (NICE), Guidance for the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technology Appraisal Guidance No. 36, 2002. Available online at: www.nice.org.uk.
15. Coyle D, Judd M, Blumenauer B, Cranney A, Maetzel A, Tugwell P, et al. Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation (Technology report no 64). Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2006.
16. Cooper N. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000;39:28-33.
17. Gabriel S, Coyle D, Moreland L. A clinical and economic review of disease modifying antirheumatic drugs. Pharmacoeconomics 2001;19:715-28.
18. Lyseng-Williamson K, Foster R. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004;22:107-32.
19. Lyseng-Williamson K, Plosker G. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004;22:1071-95.
20. Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference? Med Decis Making 2005;25:520-33.
21. Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 2005;65:473-96.
22. Wolfe F, Michaud K, Pincus T. Do rheumatology cost-effectiveness analyses make sense? Rheumatology 2004;43:4-6.
23. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002.
24. Lindkvist E, Saxne T, Geborek P, Eberhardt K. Ten-year outcome in a cohort of early rheumatoid arthritis patients - health status, disease process and damage. Ann Rheum Dis 2002;61:1055-9.
25. Wolfe F, Fries F. ARAMIS today: moving toward internationally distributed databank systems for follow-up studies. Clin Rheumatol 1987;6(Suppl 2):93-102.
26. Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5yrs follow up in 732 patients from the Early RA Study. Rheumatology (Oxford) 2000;39:603-33.
27. Fries F. Reevaluating the therapeutic approach to rheumatoid arthritis: the 'Sawtooth' strategy. J Rheumatol 1990;17(Suppl):12-15.
28. Maetzel A, Tugwell P, Boers M; the OMERACT group. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a reference case. J Rheumatol 2003;30:891-6.
29. Jönsson B. Quality of life and health economics. Where is the link? Scand J Gastroenterol 1996;31(Suppl 221):33-6.
30. Torrance G. Measurement of health state utilities for economic appraisal. A review. J Health Econ 1986;5:1-30.
31. Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care. Boston: Kluwer Academic Publishers, 1997.
32. Kobelt G. Health economics: introduction to economic evaluation. London: Office of Health Economics, 1996.
33. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. York: Centre for Health Economics, University of York, 1995.
34. Torrance G, Zhang Y, Feeny D, Furlong W, Barr R. multi-attribute preference functions for a comprehensive health status classification system. Hamilton, Ontario: McMaster University, 1992. CHEPA working paper series no. 92-18.
35. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82.
36. Hurst N, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
37. Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K. Modelling the progression of rheumatoid arthritis. A two-country model to estimate costs and consequences RA. Arthritis Rheum 2002;46:2310-19.
38. Ware J, Sherbourne C, McHorney C. The MOS 36-item short form health survey. Med Care 1993;31:247-63.
39. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
40. Kobelt G, Eberhardt K, Jönsson L, Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
41. Lajas C, Abasolo L, Bellajdel B, Hernandez-Garcia C, Carmona L, Vargas E, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003;49:64-70.
42. Hulsemann JL, Ruof J, Zeidler H, Mittendorf T. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol Int 2006;26:704-11.
43. Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976;39:21-36.
44. Koopmanschap M, Rutten F, van Ineveld B, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89.
45. Verstappen SM, Boonen A, Verkleij H, Bijlsma JW, Buskens E, Jacobs JW. Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis 2005;64:1754-60.
46. Pentek M, Kobelt G, Szekanecz Z, Poor G, Cziriak L, Rjokovich B, et al. Burden of illness, costs and outcomes of rheumatoid arthritis in Hungary. Value Health 2005;8:A29.
47. Wong J, Ramey D, Singh G. Long-term morbidity, mortality and economics of rheumatoid arthritis. Arthritis Rheum 2001;44:2746-9.
48. Scott D, Pugner K, Kaarela K, Doyle DW, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000;39:122-32.
49. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000;43:14-21.
50. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-18.
51. Genovese M, Martin R, Fleischman R, Keystone E, Bathom J, Tsuji W. Etanercept (Enbrel) in early erosive rheumatoid arthritis (ERA-Trial): 4 year clinical and radiographic data. Ann Rheum Dis 2003;62(Suppl 1):183.
52. Klareskog L, Van der Heijde D, Jager J, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: a double-blind randomised controlled trial. Lancet 2004;363:675-81.
53. National guidelines for monitoring second line drugs. British Society of Rheumatology 2000 (www.rheumatology.org.uk).
54. Symmons D, Silman A. The epidemiology of rheumatoid arthritis. In Wolfe F, Pincus T, editors. Rheumatoid arthritis: pathogenesis, assessment, outcome and treatment. New York: Marcel Dekker, 1994: 131-50.
55. Sorensen J. Health care costs attributable to the treatment of rheumatoid arthritis. Scand J Rheumatol 2004;33:399-404.